10.18
0.10%
-0.0101
Precedente Chiudi:
$10.19
Aprire:
$10.1799
Volume 24 ore:
225
Relative Volume:
0.01
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+0.20%
1M Prestazione:
+0.59%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Oaktree Acquisition Corp Iii Life Sciences Stock (OACCU) Company Profile
Nome
Oaktree Acquisition Corp Iii Life Sciences
Settore
Industria
Telefono
-
Indirizzo
-
Confronta OACCU con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
OACCU
Oaktree Acquisition Corp Iii Life Sciences
|
10.18 | 0 | 0 | 0 | 0 | 0.00 |
LION
Lionsgate Studios Corp
|
6.92 | 2.00B | 3.13B | 50.80M | 555.00M | 0.1772 |
BZAI
Blaize Holdings Inc
|
7.56 | 792.89M | 0 | 0 | 0 | 0.00 |
AACT
Ares Acquisition Corporation Ii
|
11.00 | 687.50M | 0 | 16.92M | -1.35M | 0.29 |
ANNA
Aleanna Inc
|
11.50 | 466.44M | 0 | 0 | 0 | 0.00 |
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.51 | 453.24M | 0 | 1.30M | 0 | 0.0301 |
Oaktree Acquisition Corp Iii Life Sciences Borsa (OACCU) Ultime notizie
Private equity drives dealmaking across sectors with $870m+ in disclosed transactions - Alternatives Watch
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Yearend 2024 SPAC Market Update & Outlook - Business Wire
The Roundup: Top Takeaways from Oaktree’s Quarterly Letters – December 2024 Edition - Oaktree Capital
Oaktree Acquisition Corp. III Announces Unit Separation, Nasdaq Trading Updates for December - StockTitan
OACCU News Today | Why did Oaktree Acquisition Corp. III Life Sciences stock go up today? - MarketBeat
Oaktree Acquisition Corp. III Life Sciences’ (NASDAQ:OACCU) Quiet Period Will End on December 3rd - Defense World
Pacific Valley Bancorp (OTCMKTS:PVBK) and Pinnacle Financial Partners (NASDAQ:PNFP) Critical Comparison - Defense World
Trinity Investments Acquires The Standard, London Alongside Oaktree and Partners Group - Business Wire
Oaktree Acquisition Corp. III Life Sciences’ US$175 Million Initial Public Offering - Global Legal Chronicle
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
White & Case advises underwriters on Oaktree Acquisition Corp. III Life Sciences’ US$175 million IPO - White & Case LLP
U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names - Seeking Alpha
Spirit Aero losses deepen, burns cash as Boeing strike bites - Yahoo Canada Finance
Oaktree Acquisition Corp. III Life Sciences Announces Pricing of $175 Million Initial Public Offering - StockTitan
Deal Watch: Big Week for Private Equity, Private Credit and Kirkland - Law.com
US IPO Weekly Recap: Standard Aero Soars In 7-IPO Week, While Big Tech Names Join Pipeline - Seeking Alpha
IPO NewsUS IPO Weekly Recap: Standard Aero soars in 7-IPO week, while big tech names join pipeline - Renaissance Capital
Envestnet approves Bain acquisition, Warburg Pincus leads $125m Series E - Alternatives Watch
Verona inks financing deal worth up to $650M ahead of COPD decision - Endpoints News
Exclusive | Oaktree Spins Out Transportation-Infrastructure Group - The Wall Street Journal
Special Purpose Acquisition Companies - Ropes & Gray LLP
Private Credit Funds Get Moody’s Warning on Problem Loans - Bloomberg
Ares Takes Fresh Aim at Healthcare Through New Fund - The Wall Street Journal
IRA Capital Acquires 237,000 Square-Foot Life Science/R&D Campus in Columbus - Newsfile
PE Weekly: Investment Bank Spins Out a New PE Firm - Middle Market Growth
The Forest Road Company Continues Aggressive Expansion With the Addition of Former Oaktree and Elliott Executives - Business Wire
Big M&A deals of 2023, From jerrycans to cheeseheads - Plastics News
Oaktree Raises About $3 Billion for Latest Special-Situations Fund - The Wall Street Journal
Hines, Oaktree to Build Advanced Manufacturing Campus in Fremont - Globe St.
Private credit filling void left by highly regulated banks, Oaktree's Panossian says - Pensions & Investments
Stock Market News Today - StockTitan
Why Danaher Is One Of My Favorite Long-Term Investments (NYSE:DHR) - Seeking Alpha
Spotlight: Golden Triangle Offices & Laboratories - Savills
Redevelopment of Canary Wharf office building into life sciences space gets green light - BE News
Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings - StockTitan
Record Q1 for Golden Triangle life sciences real estate investment - Insider Media
Melissa Sawyer - Sullivan & Cromwell LLP
Chad D. Ehrenkranz - Sidley Austin LLP
Harrow Announces New $100 Million Secured Credit Facility with Oaktree - Business Wire
SPACs in Healthcare: The Hot Ticket has Cooled off - Managed Healthcare Executive
Oaktree Capital Management approves new term loan for Innocoll - World Business Outlook
UK Life Sciences and Healthcare Newsletter - Dechert LLP
Oxford Properties Makes $134M LA Life Science Debut - Commercial Property Executive
Inspired by Airbnb, Hims & Hers offers 10,000 free medical visits to displaced Afghan refugees - TechCrunch
Money Moves: With acquisition, DC's EveryAction is now part of a social impact-focused SaaS company valued at $2B - Technical.ly
How does Hims & Hers make money? - VatorNews
Direct Lending: Benefits, Risks and Opportunities - Oaktree Capital
Hims, the telehealth startup, saw its shares slip in their trading debut -- and that's fine with its CEO - TechCrunch
A look back at the how tech changed the pharma landscape in 2020 - Mobihealth News
Axa IM acquires life sciences real estate developer Kadans - Funds Europe Magazine
Hims & Hers Appoints Two New Board Members: Lynne Chou O’Keefe & David Wells - Femtech Insider
Oaktree Acquisition Corp Iii Life Sciences Azioni (OACCU) Dati Finanziari
Non sono disponibili dati finanziari per Oaktree Acquisition Corp Iii Life Sciences (OACCU). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):